Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

The findings were in line with those of a large retrospective cohort study that showed that patients treated with GLP-1 ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

Lots of stars are slimming down, igniting a Hollywood trend that raises concerns about the return of dangerous beauty standards.

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

By now we have all heard about Semaglutide (Ozempic) and Tirzepatide (Mounjaro).  Whether you have used it yourself or know of someone who has, we know how effective ...

Whoopi Goldberg has stunned in her latest looks showing off her 100+ pound weight loss after taking popular weight loss drug ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...